Navigation Links
Georgetown researcher: 2 or more drinks a day may increase pancreatic cancer risk
Date:3/3/2009

Washington, DC -- Men and women who consume two or more alcoholic drinks a day could increase their risk of developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.

Previous studies have been unable to confirm the association between drinking and the risk of pancreatic cancer, but most studies depended on a person's recall of alcohol intake. Still, many hypothesize about the relationship between alcohol and pancreatic cancer because drinking is associated with the risk of pancreatitis and diabetes, and both of these conditions are known risk factors for developing the disease.

Unlike the previous studies, this current research pools data collected prospectively from 14 research studies, which included 862,664 individuals (319,716 men and 542,948 women). Data collected prospectively means information about dietary and environmental exposures were collected prior to diagnosis with pancreatic cancer. Researchers identified 2,187 individuals diagnosed with pancreatic cancer during the study.

"This is one of the largest studies ever to look at dietary factors in relation to pancreatic cancer risk," says lead author Jeanine M. Genkinger, Ph.D., an assistant professor at Georgetown University's Lombardi Comprehensive Cancer Center.

If individuals consumed 30 or more grams of alcohol per day (approximately two drinks), compared with no alcohol per day, their risk of pancreatic cancer was slightly increased, researchers said. A drink is defined as 12 ounces of beer, four ounces of wine, or 1.5 ounces of 80-proof distilled liquor.

Although, there was no statistically significant difference between men and women when comparing alcohol intake with risk of pancreatic cancer, the association was seen in women at two or more drinks per day. Comparatively, the researchers observed a higher risk among men w
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Georgetown University Med Center reproductive health researchers tackle public health concerns
2. Georgetown University Medical Center Collaborates with Indivumed to Develop Cancer Research Database
3. Georgetown Medical Center collaborates to develop cancer research database
4. No More Needles? Georgetown University Teams with Gentag and SAIC to Develop New Glucose Sensor Technology with Wireless Connection to Cell Phones
5. Georgetown researchers find stem cell marker controls 2 key cancer pathways
6. Georgetown U student selected for prestigious Bouchet Society
7. Georgetown leads major effort to combat disparities in DC stroke care
8. New USAID grant helps Georgetown meet unmet family planning needs worldwide
9. OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness
10. UT Southwestern researcher: Supplemental breast ultrasound boosts cancer detection
11. Researcher: Pumpkin Eases Stress
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6